This strategy was chosen because DNA methylation is abnormal in cancer cells [34] and because combination of DNA methylation and HDAC inhibitors has efficacy in patients with advanced non-small cell lung cancer [35]. Here, HDAC9 is linked to non-small cell lung carcinoma.